Calcipotriol zur Prävention der Polymorphen Lichtdermatose - Calcipotriol und PLD

INTERVENTION: Trade Name: Psorcutan cream Pharmaceutical Form: Cream INN or Proposed INN: Psorcutan Creme Pharmaceutical form of the placebo: Cream Route of administration of the placebo: Cutaneous use CONDITION: Polymorphic light eruption ; MedDRA version: 9.1 Level: LLT Classification code 10036087 Term: Polymorphic light eruption PRIMARY OUTCOME: Main Objective: To investigate the efficacy of a pretreatment with calcipotriol in polymorphic light eruption. Primary end point(s): PLD Score Secondary Objective: INCLUSION CRITERIA: Patients with Polymorphous light eruption Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range